A dry powder inhaler formulation provides excellent protection against pneumonia-causing bacteria, scientists report. Community-acquired pneumonia, a type of lung inflammation contracted outside ...

Tyvaso DPI is an investigational drug-device combination therapy consisting of a dry powder formulation of treprostinil. The Food and Drug Administration (FDA) has accepted for Priority Review the ...

A case study will also be presented, in which an inhaled formulation of the antibody bevacizumab demonstrated 24-month stability at 25°C. Key Learning Objectives. Understand formulation approaches for ...

Successful drug delivery via a dry powder inhaler is determined by the API physicochemical properties, the formulation composition and process, the device and operating conditions, the patient–device ...

LONDON, Dec. 17, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ: VRNA) (“Verona Pharma”), a clinical stage biopharmaceutical compa ...

Aptar Pharma Enters into Exclusive Agreement with Cambridge Healthcare Innovations to Commercialize the Quattrii Dry Powder Inhaler Platform Contacts Ciara Jackson Aptar Pharma +49 151 1951 6502 ...

Rein Therapeutics Granted Two Patents Covering the Novel Formulation and Administration Methods of Dry Powder LTI-03 for the Treatment of Respiratory Diseases. PR Newswire. AUSTIN, Texas, April 23 ...

Glaxo Smith Kline (GSK) announced in May that Flovent HFA, a metered-dose inhaler, as well as Flovent Diskus, a dry powder inhaler, would be discontinued as of Dec. 31, 2023. Experts weigh in.

They are convenient and easy to use, and they offer a number of advantages over other inhaler devices. The global dry powder inhaler device market was valued at $1.4 billion in 2018, and it is ...

Immediate opportunity to increase capacity for formulation and early asset development in upgraded Boston area R&D spaceNon-cash deal includes royalty-free iSPERSE™ technology license in ...

CRYSTAL LAKE, Ill., November 07, 2024--Aptar Pharma Enters into Exclusive Agreement with Cambridge Healthcare Innovations to Commercialize the Quattrii Dry Powder Inhaler Platform ...